Mediators of Inflammation

Clinical Study

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial

Table 2

Urinary eicosanoid levels- absolute and 24-week changes, by study arm.


	RAL	Within-group	PI/NNRTI	Within-group	Between-group

F₂-IsoP
Week 0	2.41 (1.96, 3.04)		1.89 (1.35, 3.77)		0.28
Week 24	2.39 (1.55, 2.65)		2.20 (1.17, 3.10)		0.96
Week 24 change	−0.12 (−0.3, +0.08)	0.13	−0.13 (−0.62, +0.60)	0.70	0.82
PGE-M
Week 0	5.95 (4.25, 9.52)		9.37 (5.36, 13.48)		0.08
Week 24	6.96 (2.14, 8.51)		8.84 (5.77, 13.26)		0.08
Week 24 change	+1.07 (−3.26, +3.08)	0.82	−1.25 (−3.29, +3.23)	0.81	0.77
PGI-M
Week 0	0.07 (0.05, 0.10)		0.13 (0.08, 0.21)		0.005
Week 24	0.08 (0.06, 0.13)		0.13 (0.10, 0.18)		0.04
Week 24 change	+0.02 (−0.002, +0.05)	0.04	−0.004 (−0.04, +0.03)	0.62	0.08
TxB₂
Week 0	0.34 (0.14, 0.70)		0.55 (0.29, 0.77)		0.09
Week 24	0.44 (0.27, 0.64)		0.44 (0.35, 0.61)		0.56
Week 24 change	+0.10 (−0.04, +0.13)	0.22	−0.02 (−0.20, +0.03)	0.25	0.07

Values shown are median (interquartile range).
F₂-IsoP = F₂-isoprostanes; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; PGE-M = prostaglandin E₂ metabolite; PGI-M = prostacyclin metabolite; RAL = raltegravir; TxB₂ = thromboxane B₂.